We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Genetic Technologies Ltd | NASDAQ:GENE | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.29 | 2.18 | 2.38 | 2.38 | 2.21 | 2.31 | 13,462 | 01:00:00 |
To regain compliance with the Listing Rule, the Company’s American Depositary Shares (ADS) were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on December 28, 2023. Nasdaq has stated that this matter is now closed.
Enquiries
Investor RelationsAdrian MulcahyAutomic MarketsM: +61 438 630 411E: adrian.mulcahy@automicgroup.com.au
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular, and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
1 Year Genetic Technologies Chart |
1 Month Genetic Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions